Biopharma contract research organization (CRO) ClinChoice has raised $150 million Series-E round financing. The firm’s global headquarters is in Shanghai, with its U.S. operations emanating from Fort Washington.
The company aids pharmaceutical, biotechnology, medical device, and consumer clients in bringing approved drugs and devices to market. Its customer base includes startups.
The investment was led by Legend Capital and co-invested by Taikang Life Insurance, Sherpa Healthcare Partners (all of Beijing), and existing shareholders. Proceeds of the financing will be used to fund the company’s continued business expansion and innovative service offering worldwide.
According to ClinChoice Global Chairman and CEO Ling Zhen, “We thank the investors for their trust in ClinChoice. This round of capital investment fully validates ClinChoice’s rapid growth and future potential in the field of clinical CRO.
“With the new round of financing, we will further enhance our innovative service offering and continue business expansion by organic growth and M&A, in order to better serve our clients worldwide,” he concluded.
More on this story is online.
